Cervical cancer: the second-generation vaccines move forward.
Tuma
Rabiya S
RS
D052685:Alphapapillomavirus / Q000276:immunology; D000818:Animals; D003906:Developing Countries; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008403:Mass Screening; D050725:Papillomavirus E7 Proteins / Q000187:drug effects; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics / Q000627:therapeutic use*; D011230:Precancerous Conditions / Q000517:prevention & control; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination / Q000191:economics*
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18